biotech binary events Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	1/14/2011 5:13:23 PM
	of 295

Salix Pharma initiated with a Reduce at Duncan Williams: . SLXP was initiated with a Reduce at Duncan Williams. Though firm views the co as a successful gastroenterology franchise with a promising future growth trajectory, they are cautious re-Xifaxan Irritable Bowel Syndrome approval ahead of the March 7 PDUFA. They believe that there is a 50% risk that the FDA will request long-term safety data and/or repeated use trials and believe that investors should consider these possibilities since IBS approval may already be included in the stock price. Additionally, firm's Xifaxan revenue estimates are below management and consensus expectations.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next